One underlying reason may be incomplete records in the electronic medical system and more patients receiving CTLA-4 inhibitor in clinical trials, as CTLA-4 inhibitors are associated with an increased risk of colitis and hepatitis compared to PD-1/PD-L1 inhibitors (Wang et al., 2017). The gene discussed is CTLA4; the disease is Hepatitis.